{"id":1213,"date":"2025-10-15T12:23:16","date_gmt":"2025-10-15T16:23:16","guid":{"rendered":"https:\/\/www.yorku.ca\/osgoode\/ip-innovation-clinic\/?p=1213"},"modified":"2025-12-09T11:44:00","modified_gmt":"2025-12-09T16:44:00","slug":"the-clinic-effect-weardoxx-smart-wearable-devices","status":"publish","type":"post","link":"https:\/\/www.yorku.ca\/osgoode\/ip-innovation-clinic\/2025\/10\/15\/the-clinic-effect-weardoxx-smart-wearable-devices\/","title":{"rendered":"WearDOXX: Smart wearable devices for early disease detection and personalized healthcare\u00a0\u00a0"},"content":{"rendered":"\n
<\/div>\n\n\n\n

In the first of our new series, The Clinic Effect<\/strong>, we highlight current and past IP Innovation Clinic clients from our 15-year history of helping advance IP sophistication and support in Ontario and across Canada<\/em>.<\/p>\n\n\n

\n
\"WearDOXX<\/figure>\n<\/div>\n\n\n

What does your sweat reveal about you? <\/strong>According to Dr. Razieh (Neda) Salahandish<\/a>, Assistant Professor in the Department of Electrical Engineering and Computer Science at the Lassonde School of Engineering, ¿ì²¥ÊÓƵ, quite a lot. Neda and the team she leads at LAB-HA (Laboratory of Advanced Biotechnologies for Health Assessment) have developed WearDOXX<\/a>, a wearable biosensing platform that analyzes sweat to detect early-stage biomarkers of diseases such as autoimmune disorders, breast cancer, Alzheimer\u2019s, and epilepsy.  <\/p>\n\n\n\n

<\/div>\n\n\n\n

The Innovation<\/em><\/strong> <\/em> <\/p>\n\n\n\n

With a background in biomedical engineering, Neda specializes in wearable biosensors, microfluidic diagnostics, and AI-integrated health monitoring systems designed to address real-world healthcare challenges through translational innovation.  <\/p>\n\n\n\n

Neda created WearDOXX to address the lack of accessible, non-invasive, and proactive screening tools for early detection of chronic and cancer\/neurological diseases. Conventional diagnostics often rely on costly, invasive procedures, such as imaging, EEGs, or spinal taps, that are not available to many people, especially those in rural or underserved communities.   <\/p>\n\n\n\n

The WearDOXX platform combines microfluidic colorimetric sensing\u2014a process that uses color change in a solution to detect the presence of certain substances\u2014with AI-enabled smartphone analysis. The platform provides a non-invasive, real-time solution for early disease detection that can be used in home and community settings.    <\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

\"WearDOXX enables individuals to monitor their health with a simple, wearable patch, democratizing access to early screening.\u201d - Dr. Neda Salahandish<\/em>  <\/strong><\/mark><\/p>\n<\/blockquote>\n<\/blockquote>\n\n\n\n

<\/div>\n\n\n\n

The Impact <\/em><\/strong> <\/em> <\/p>\n\n\n\n

The global market size for the wearable device industry, which WearDOXX falls into, was valued at an estimated $45 billion in 2024 and is expected to reach $151.8 billion by the end of 2029.1<\/a><\/sup> That is a compound annual growth rate (CAGR) of 27.5%, driven primarily by the rising prevalence of chronic conditions, such as respiratory diseases, cancer, diabetes, and heart disease.   <\/p>\n\n\n\n

Neda believes that WearDOXX can contribute to job creation and social betterment in Canada through enabling early detection outside of clinical settings. This will, in turn, help reduce healthcare disparities, lower system costs, and improve health outcomes, particularly for marginalized populations. Neda adds, \u201cSocially, this empowers individuals to take control of their health; economically, it helps decrease the burden of late-stage disease care while contributing to Canada\u2019s innovation economy through health tech commercialization and job creation.\u201d  <\/p>\n\n\n\n

<\/div>\n\n\n\n

WearDOXX\u2019s targeted demographic includes,   <\/p>\n\n\n\n